Managing Chronic Kidney Disease in Patients With Diabetes
This site is intended for healthcare professionals

COMMENTARY

Managing Chronic Kidney Disease in Patients With Diabetes

Sylvia Rosas, MD, MSCE; Mark Harmel, MPH, CDCES

Disclosures

June 09, 2022

2

This transcript has been edited for clarity.

The American Diabetes Association has recently released the 2022 Standards of Medical Care in Diabetes. Among the highlights are the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to slow the progression of kidney and cardiovascular disease, the use of nonsteroidal mineralocorticoid receptor agonists, such as finerenone, to slow progression of kidney disease, and the use of the new race-free equation that is currently being implemented by the National Kidney Foundation and the American Society of Nephrology.

The SGLT2 inhibitors have been shown to slow progression of kidney disease, decrease albuminuria, and have a cardiovascular benefit in patients with and without diabetes.

Chronic kidney disease affects 37 million Americans and 850 million people around the world. Diabetes is the most common cause of kidney disease in the United States. Unfortunately, chronic kidney disease is an asymptomatic disease, so symptoms only appear very late in the disease when people are already needing dialysis or transplantation.

Therefore, screening for chronic kidney disease in high-risk populations, such as those who have diabetes, hypertension, or a family history of kidney disease, is of vital importance. Unfortunately, not everybody who is at high risk is being screened; therefore, it's very important that when you discuss it with your provider, if you're at high risk, you at least have this test annually.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....